SCHEDULE: Vanguard Group Reports Zero Dexcom Stake Post-Realignment

The Vanguard Group has reported a 0% beneficial ownership in Dexcom Inc. common stock following an internal realignment that disaggregated reporting responsibilities.

Summary

• The Vanguard Group filed an Amendment No. 14 to Schedule 13G for Dexcom Inc. common stock.
• As of March 13, 2026, The Vanguard Group reported 0% beneficial ownership of Dexcom Inc. common stock.
• This change is due to an internal realignment on January 12, 2026, where certain subsidiaries and business divisions now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The filing certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Dexcom Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, procedural filing. It reflects an internal organizational change at The Vanguard Group rather than a direct positive or negative event for Dexcom Inc. or a change in investment sentiment.

Positives

• Increased transparency in beneficial ownership reporting due to disaggregation of Vanguard's holdings.

Negatives

• The Vanguard Group no longer directly reports beneficial ownership of Dexcom shares, which might reduce the visibility of their aggregate holdings under the parent entity.

Risks

• NA

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group frequently adjust their internal reporting structures, which can lead to changes in how beneficial ownership is disclosed. This disaggregation aligns with SEC guidance for large investment complexes, providing more granular insight into specific fund or division holdings rather than a single aggregate figure. This trend reflects a broader move towards greater transparency in institutional asset management.

Comparison to Industry Standards

• This filing reflects a standard practice for large investment managers like BlackRock or State Street, which also manage vast portfolios across numerous funds and often disaggregate their reporting to comply with regulatory guidance and provide clearer ownership breakdowns.
• The realignment and subsequent reporting of 0% beneficial ownership by the parent entity, while subsidiaries report separately, is consistent with how other major asset managers handle complex ownership structures, particularly after internal reorganizations.

Corporate Governance

Stakeholder Impact

• Shareholders (Dexcom): Provides clarity on the reporting structure of a major institutional investor, though the actual underlying holdings by Vanguard's various funds may still exist, just reported differently.
• Investors (Vanguard Funds): The realignment aims to provide more precise reporting of beneficial ownership by specific funds or divisions.

Next Steps

• Subsidiaries or business divisions of The Vanguard Group, Inc. will report their beneficial ownership of Dexcom Inc. separately.

Key Dates

Recommendation

This filing is purely procedural, detailing an internal reporting realignment by The Vanguard Group. It does not provide any information about Dexcom Inc.'s financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as there's no new fundamental data to alter an existing investment thesis.

Keywords

Dexcom Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Management, Corporate Governance